Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

INmune Bio Inc

Healthcare US INMB

1.345USD
0.03(1.89%)

Last update at 2026-06-04T17:46:00Z

Day Range

1.311.40
LowHigh

52 Week Range

6.5014.74
LowHigh

Fundamentals

  • Previous Close 1.32
  • Market Cap200.79M
  • Volume202181
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.13M
  • Revenue Per Share TTM0.007
  • Gross Profit TTM 0.37M
  • Diluted EPS TTM-1.92

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -27.29900M -30.34000M -12.09916M -7.67831M -12.44002M
Minority interest - - - - -
Net income -28.64700M -30.34000M -12.09916M -9.14263M -12.44002M
Selling general administrative 9.26M 8.79M 6.32M 6.02M 11.33M
Selling and marketing expenses - - - - -
Gross profit 0.37M 0.18M 0.01M 77.69M 0.00000M
Reconciled depreciation - - - - -
Ebit -25.95100M -29.15300M -12.09916M -7.75600M -12.44002M
Ebitda -25.95100M -29.15300M -12.22768M -10.84000M -12.44002M
Depreciation and amortization -1.34800M -1.18700M - -3.08400M -
Non operating income net other - -1.18700M 0.13M 0.08M -
Operating income -25.95100M -29.15300M -12.22768M -7.75600M -12.44002M
Other operating expenses 26.32M 29.33M 12.24M 9.30M 12.44M
Interest expense 1.35M 1.19M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - 0.08M -
Net interest income - - - 0.08M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.35M 1.19M -0.12852M 1.46M 0.00000M
Total revenue 0.37M 0.18M 0.01M 77.69M 0.00000M
Total operating expenses 26.32M 29.33M 12.24M 9.30M 12.44M
Cost of revenue - - - - 0.00000M
Total other income expense net -1.34800M -1.18700M 0.13M 0.08M 0.00000M
Discontinued operations - - - - -
Net income from continuing ops -25.95100M -30.34000M -12.09916M -7.67831M -12.44002M
Net income applicable to common shares -27.29900M -30.34000M -12.09916M -7.67831M -12.44002M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 57.00M 81.80M 99.94M 40.66M 24.47M
Intangible assets 16.51M 16.51M 16.51M 16.51M 16.51M
Earning assets - - - - -
Other current assets 1.65M 4.03M 7.80M 2018.84M 769.25M
Total liab 18.86M 21.69M 19.72M 1.90M 0.86M
Total stockholder equity 38.14M 60.10M 80.22M 38.75M 23.61M
Deferred long term liab - - - - -
Other current liab 8.43M 0.62M 0.47M 0.19M 692.09M
Common stock 0.82M 0.02M 0.02M 0.01M 0.01M
Capital stock 0.82M 0.02M 0.02M 0.01M 0.01M
Retained earnings -121.02200M -91.01400M -63.71500M -33.37534M -21.27618M
Other liab - 0.55M 0.20M - -
Good will - - - - -
Other assets 0.00000M 0.10M 0.10M 0.16M -
Cash 35.85M 52.15M 74.81M 21.97M 7.00M
Cash and equivalents - - - - -
Total current liabilities 18.46M 10.92M 4.36M 1.78M 0.70M
Current deferred revenue 0.49M - - - -692.09100M
Net debt -25.41100M -36.84300M -59.57600M -21.80672M -6.82707M
Short term debt 10.04M 5.09M 0.07M 0.03M 0.00829M
Short long term debt 9.92M 5.00M - - -
Short long term debt total 10.44M 15.31M 15.23M 0.16M 0.17M
Other stockholder equity 158.34M 151.80M 143.92M 72.10M 44.88M
Property plant equipment - 0.51M 0.73M 0.16M 0.19M
Total current assets 39.94M 64.67M 82.61M 23.99M 7.76M
Long term investments - - - - -
Net tangible assets - 43.59M 63.71M 22.24M 7.10M
Short term investments - - - - -
Net receivables 2.44M 8.46M 5.50M 1.80M 0.65M
Long term debt - 9.70M 14.46M - -
Inventory - 0.03M -5.50400M -2018.61891M -769.12911M
Accounts payable 7.94M 5.21M 3.81M 1.55M 0.69M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.79900M -0.69900M 0.00100M 0.01M -0.00851M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.02M 0.01M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - -91.01400M -63.71500M -33.37534M -21.27618M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.13M 0.10M 0.10M 0.10M 16.71M
Deferred long term asset charges - - - - -
Non current assets total 17.06M 17.12M 17.34M 16.67M 16.71M
Capital lease obligations 0.52M 0.61M 0.78M 0.16M 0.17M
Long term debt total - 9.70M 14.46M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.00000M -15.00000M - - 0.00000M
Change to liabilities 1.75M 2.46M 1.08M -0.13167M 0.51M
Total cashflows from investing activities - -15.00000M -15.00000M -15.00000M -15.00000M
Net borrowings - 14.95M 14.95M 14.95M 14.95M
Total cash from financing activities 0.73M 96.36M 23.90M 12.21M 0.90M
Change to operating activities -4.26600M -5.34700M -1.03194M -0.12921M -0.13438M
Net income -27.29900M -30.34000M -12.09916M -7.67831M -12.44002M
Change in cash -22.65700M 52.84M 14.97M 6.81M -1.18451M
Begin period cash flow 74.81M 21.97M 7.00M 0.19M 1.37M
End period cash flow 52.15M 74.81M 21.97M 7.00M 0.19M
Total cash from operating activities -22.68600M -28.50400M -8.94365M -5.38466M -2.05899M
Issuance of capital stock 0.70M 80.25M 24.91M 12.21M 0.90M
Depreciation 0.24M 0.13M - - -
Other cashflows from investing activities - -15.00000M -15.00000M -15.00000M -15.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - -1.11793M - -
Sale purchase of stock 0.03M 81.41M -1.01200M 12.21M 0.90M
Other cashflows from financing activities 0.03M 16.10M 89.76M - -
Change to netincome 7.15M 4.80M 3.11M 4.10M 10.00M
Capital expenditures 0.00000M 15.00M 0.00000M 0.00000M 0.00000M
Change receivables 0.23M - - - -
Cash flows other operating -4.75700M -5.54600M -1.03194M -1.67121M -0.13438M
Exchange rate changes - -0.01000M 0.02M -0.01504M -0.02551M
Cash and cash equivalents changes -21.95700M 52.84M 14.97M 6.81M -1.18451M
Change in working capital -2.86400M -3.08600M 0.04M -0.26088M 0.38M
Stock based compensation 7.15M 4.80M 3.11M 4.10M 10.00M
Other non cash items 0.33M 0.13M -2.96000M -1.54200M 1.94M
Free cash flow -22.68600M -43.50400M -8.94365M -5.38466M -2.05899M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
INMB
INmune Bio Inc		 0.03 1.89% 1.34 - - 1208.36 4.91 1044.41 -5.4431
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Inc

225 NE Mizner Blvd., Boca Raton, FL, United States, 33432

Key Executives

Name Title Year Born
Dr. Raymond Joseph Tesi M.D. Co-Founder, Pres, CEO, Chief Medical Officer & Chairman 1956
Mr. David J. Moss M.B.A. CFO, Treasurer & Sec. 1970
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Chief Scientific Officer & Chief Manufacturing Officer 1963
Mr. Joshua S. Schoonover Esq. Assoc. Gen. Counsel NA
Dr. Christopher J. Barnum Head of Neuroscience NA
Dr. Raymond Joseph Tesi M.D. Co-Founder, President, CEO, Chief Medical Officer & Chairman 1956
Mr. David J. Moss M.B.A. CFO, Treasurer & Secretary 1970
Mr. Joshua S. Schoonover Esq. General Counsel NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.